Osthole prevents anti-Fas antibody-induced hepatitis in mice by affecting the caspase-3-mediated apoptotic pathway

Biochemical Pharmacology

Volumn 65, Issue 4, 2003, Pages 677-681

  Okamoto, Toshihiro ^a,b   Kawasaki, Toru ^a   Hino, Okio ^b  

^a Nippon Chemiphar Co Ltd   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

Apoptosis; Caspase 3; Coumarin; Fas; Hepatitis; Osthole

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE 3; FAS ANTIBODY; OSTHOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOSOL; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEPATITIS; HISTOPATHOLOGY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0037441385     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01606-4     Document Type: Article

References (21)

1. Hiramatsu N., Hayashi N., Katayama K., Mochizuki K., Kawanishi Y., Kasahara A., Fusamoto H., Kamada T. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 19:1994;1354-1359.
2. Mita E., Hayahsi N., Ito S., Takahara T., Hijioka T., Kasahara H., Fusamoto H., Kamada T. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem. Biophys. Res. Commun. 28:1994;468-474.
3. Hayashi N., Mita E. Fas system and apoptosis in viral hepatitis. J. Gastroenterol. Hepatol. 12:1997;S223-S226.
4. Rivero M., Crespo J., Fabrega E., Casafont F., Mayorga M., Gomez-Fleitas M., Pons-Romero F. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J. Viral Hepat. 9:2002;107-113.
5. Tarao K., Rino Y., Ohkawa S., Shimizu A., Tamai S., Miyakawa K., Aoki H., Inada T., Shindo K., Okamoto N., Totsuka S. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer. 86:1999;589-595.
6. Fox C.K., Furtwaengler A., Nepomuceno R.R., Martinez O.M., Krams S.M. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver. 21:2001;272-279.
7. Minana J.B., Gomez-Cambronero L., Lloret A., Pallardo F.V., Del Olmo J., Escudero A., Rodrigo J.M., Pelliin A., Vina J.R., Vina J., Sastre J. Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology. 35:2002;1205-1214.
8. Neuman M.G. Apoptosis in diseases of the liver. Crit. Rev. Clin. Lab. Sci. 38:2001;109-166.
9. Ko T.N., Wu T.S., Liou M.J., Huang T.F., Teng C.M. Vasorelaxation of rat thoracic aorta caused by osthole isolated from Angelica pubescens. Eur. J. Pharmacol. 219:1992;29-34.
10. Teng C.M., Lin C.H., Ko F.N., Wu T.S., Huang T.F. The relaxant action of osthole isolated from Angelica pubescens in guinea-pig trachea. Naunyn Schmiedebergs Arch. Pharmacol. 349:1994;202-208.
11. Hoult J.R.S., Payá M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen. Pharmacol. 27:1996;713-722.
12. Gantner F., Leist M., Lohse A.W., Germann P.G., Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice. The role of tumor necrosis factor. Hepatology. 21:1995;190-198.
13. Mizuhara H., Uno M., Seki N., Yamashita M., Yamaoka M., Ogawa T., Kaneda K., Fujii T., Senoh H., Fujiwara H. Critical involvement of interferon gamma in the pathogenesis of T-cell activation - associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology. 23:1996;1608-1615.
14. Okamoto T., Yoshida Y., Kobayashi T., Okabe S. Inhibition of concanavalin A-induced hepatitis by coumarin derivatives. Jpn. J. Pharmacol. 85:2001;95-97.
15. Ogasawara J., Watanabe-Fukuyama R., Adachi M., Matsuzawa A., Kasugai T., Kitayama Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 364:1993;806-809.
16. Karmen A., Wroblewski F., LaDue J.S. Transaminase activity in human blood. J. Clin. Invest. 34:1955;126-133.
17. Okamoto T., Hino O. Strategy to develop drugs which prevent hepatocarcinogenesis - from hypercarcinogenic state to hypocarcinogenic state. Recent Res. Dev. Cancer. 3:2001;275-282.
18. Arase Y., Ikeda K., Murashima N., Chayama K., Tsubota A., Koida I., Suzuki Y., Saitoh S., Kobayashi M., Kumada H. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 79:1997;1494-1500.
19. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
20. Rodriguez I., Matsuura K., Ody C., Nagata S., Vassali P. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J. Exp. Med. 184:1996;2067-2072.
21. Van Rossum T.G., Vulto A.G., Hop W.C., Brouwer J.T., Niesters H.G., Schalm S.W. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J. Gastroenterol. Hepatol. 14:1999;1093-1099.